Clinical Trials Logo
  1. Home
  2. Malignant Melanoma Stage IV
  3. NCT00722098

Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients

Malignant Melanoma Stage IV Clinical Trial

Official title:
Melanoma Peptide-Loaded Dendritic Cell Vaccine in HLA-A*0201 Patients With Stage IV Melanoma: A Phase II Randomized Trial to Compare Vaccination With and Without Cyclophosphamide Treatment.

Clinical Trial Summary

The purpose of this study is to determine whether the combination of chemotherapy (Cyclophosphamide) and CD34-DC vaccines results in the improved rate of clinical responses for stage IV melanoma patients.

Clinical Trial Description

Vaccination of patients with metastatic melanoma using ex vivo generated dendritic cells (DCs) loaded with tumor-associated antigen(s) have been shown to induce tumor-specific immunity against melanoma antigens measured by in vitro assays and, in some cases, tumor regression. At the present time, the numbers of recorded patients with metastatic melanoma who have been treated with DC vaccinations are too small to predict with certainty the future of overall therapeutic value of DC vaccinations in the management of patients with metastatic melanoma. The purpose of this study is to gather data on feasibility and efficacy of novel combination therapy of CPA and a DC vaccine outlined in this protocol to treat metastatic melanoma. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00722098
Study type Interventional
Source Baylor Research Institute
Contact
Status Terminated
Phase Phase 2
Start date June 2008
Completion date July 2012
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03132090 - Early Therapy Response Monitoring in Melanoma Patients Using PET/MRI N/A
Completed NCT01676779 - mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma Phase 2
Terminated NCT04577729 - The IRMI-FMT Trial N/A
Completed NCT02439411 - Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain
Completed NCT00313235 - Combined Modality Treatment for Patients With Stage IV Melanoma Phase 1/Phase 2
Recruiting NCT03166397 - Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients Phase 2
Not yet recruiting NCT05304546 - Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma Phase 2
Terminated NCT03430947 - Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases Phase 2
Completed NCT01189383 - IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma Phase 1/Phase 2
Completed NCT01983124 - Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib Phase 2
Completed NCT01302496 - Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma Phase 2
Not yet recruiting NCT03493230 - Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT ) N/A